Pharma
Natco Pharma receives successful EIR from USFDA for its Telangana unit
Natco Pharma receives successful EIR from USFDA for its Telangana unit
![]()
By eHealth Network - 20 July 2017
Indian pharmaceutical company Natco Pharma Limited has received successful Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Kothur unit in Telangana, which predominantly caters to regulated international markets including the US.
Natco received the EIR from USFDA within a month of getting the final approval of Abbreviated New Drug Application (ANDA) from the US drug regulatory authority for the anti-cancer chemotherapy drug Azacitidine.
The Hyderabad-based pharma company recorded a consolidated total revenue of Rs 2,078.9 crore for the year ended on 31st March, 2017, as against Rs 1,089.7 crore a year earlier — reflecting a year-over-year growth of 90.8 per cent.
The company has this year launched a number of generic products for the Indian and US market including pomalidomide (for treatment of blood cancer) and Sofosbuvir (for treatment of Hepatitis C virus (HCV) infection).
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
